New research at the Weizmann Institute of science shows a new class of immune-activating molecules can awaken anti-tumour immunity by targeting the tumour’s own defences.
Immunotherapy, which harnesses our body’s own immune system to fight cancer, has revolutionised modern oncology. Yet despite its success with several cancers, many patients still fail to respond to therapy or experience relapse later on.
Scientists have long sought ways to pinpoint how cancer shuts down the immune response, and to flip the switch back on right at that site.
The new Weizmann study just published in Cell, suggests that the solution could lie within the tumour’s own defences.
The study focuses on macrophages – large, versatile cells that perform essential functions throughout body tissues but, when found in the tumour microenvironment, often begin collaborating with the cancer.
“For years we have known that in cancer, macrophages can be both the problem and the solution,” said Professor Ido Amit, director of Weizmann’s Immunotherapy Research Center.
“Tumours hijack them to suppress immune responses and promote their own growth. Our goal has been to re-educate these cells rather than remove them.”
In earlier studies, Amit’s team and others had identified a subgroup of macrophages-turned-tumor-allies that are particularly involved in suppressing the immune response against cancer. Their defining feature is the unusually high expression of a receptor called TREM2, which coordinates their anti-immune activity. Patients whose tumors team up with these macrophages do not respond well to treatment and tend to have lower survival rates.
In the new study, a team led by Michelle von Locquenghien, Dr Pascale Zwicky and Dr Ken Xie from Amit’s lab designed biological molecules intended to guide wayward macrophages back on track: a new type of antibodies that awaken the patient’s anti-tumour immunity by simultaneously blocking TREM2-expressing macrophages and prompting other immune cells to attack the cancer. The latter is achieved by exposing the immune cells to an activating protein called a cytokine. The researchers called this new class of immune-activating molecules MiTEs (short for Myeloid-targeted immunocytokines and natural killer/T-cell Enhancers).
A key challenge was avoiding severe side effects: When the immune system is activated too strongly across the entire body, it cannot always tell friend from foe, and can destroy healthy tissue as well as tumours.
To prevent this from happening, the researchers resorted to a clever engineering strategy. They managed to equip MiTEs with built-in molecular masks that keep the activating component, the IL-2 cytokine, silent while the molecules circulate in the body on their way to the tumour. Only when MiTEs enter the tumour is this molecular mask removed by special enzymes found only at the tumour site, enabling the cytokine to be activated where it is needed – so that the immune response is unleashed exclusively within tumours.
“The dual function of MiTEs enables them to attack the tumour from multiple immune angles at once,” explained von Locquenghien.
“These molecules are designed to turn both the tumour’s allies and its suppressive environment into its Achilles’ heel.”
Zwicky highlights the promise of this approach for improving cancer treatment, especially since it acts through immune pathways common to many cancers rather than through tumour-specific antigens.
“Because MiTEs act through immune mechanisms present in many patients and cancer types, they have the potential to be broadly applicable,” she said.
This innovative development was made possible through advanced technologies and methods, including the use of big data and of spatial transcriptomics, a technique that reveals where genes are active in a tissue.
“We mapped the spatial immune architecture in human tumours at single-cell resolution level and found that the TREM2-carrying macrophages were often positioned in direct proximity to immune killer cells that appeared exhausted,” Xie said.
“That spatial insight led us to design biological molecules that could block immune-suppressing macrophages while simultaneously delivering a localised activation signal to the killer cells, energising them to attack the tumour while minimising collateral damage.”
This approach exemplifies a growing trend in cancer immunology: designing therapies that reshape the tumour microenvironment rather than focusing solely on killing cancer cells.
“The future of immunotherapy lies in combining safety with precision – reprogramming the immune ecosystem from the inside rather than targeting cancer cells directly,” said Amit.
In studies in mice, MiTEs caused tumours to shrink and triggered widespread immune remodelling in both macrophages and immune killer cells. When tested on tissue samples of renal cell carcinoma derived from patients, they caused robust immune activation, including the awakening of killer immune cells.
To take MiTEs another step toward clinical application the scientists plan to assess their long-term safety and further explore combinations with existing therapies, including chemotherapy and radiation therapy. Preliminary results suggest that MiTEs act synergistically with existing checkpoint inhibitors, amplifying the overall immune response.
The findings provide a blueprint for a new generation of safe and programmable immunotherapies capable of overcoming resistance to current treatments in a wide spectrum of malignancies.
“Our work demonstrates that by understanding the tumours own defines mechanisms, we can turn them into opportunities,” concluded Amit.
“With MiTEs, we may have found a way to convert the tumour’s shield into the very weapon that defeats it.”
Also participating in the study were Dr Diego Adhemar Jaitin, Dr Fadi Sheban, Dr Chamutal Gur, Reut Sharet Eshed, Eyal David, Kfir Mazuz, Dr Roberto Avellino and Dr Assaf Weiner from Amit’s lab in Weizmann’s Systems Immunology Department; and Dr Adam Yalin, Dr Florian Uhlitz, Caroline Jennings Marin, Dr Ankita Sankar and Devin Mediratta from Immunai, New York, NY.
